To report the results of a pharmacist-directed blood factor stewardship program targeting off-label utilization designed to limit use to established organizational guidelines in high-risk populations. Prospective evaluation of recombinant factor VIIa and prothrombin complex concentrate orders beginning June 2013 through May 2014 and a matched retrospective cohort from June 2012 to May 2013. Matched cohorts were evaluated for 28-day mortality, change in international normalized ratio (INR), adverse events, concurrent blood product use, and cost savings. Forty-two orders for blood factor were ordered between June 2013 and May 2014, 70 orders in the year before (N 5 112). Twenty eight-day mortality was not different between the cohorts: 53.9% versus 50% (P 5 0.77). Blood factor use with underlying liver failure and active bleeding was strongly associated with 28-day mortality: odds ratio (95% confidence interval), 2.9 (1.5-7.14) and 2.91 (0.01-2.91), respectively. Blood products dispensed increased over the year with plasma products the most significant (1 vs. 4 P 5 0.004). All other clinical outcomes were nonsignificant. An annual cost savings of $375,539 was achieved, primarily through a significant reduction in recombinant factor VIIa and avoidance in high-risk patients. Use of off-label blood factors can be controlled through a pharmacist-led stewardship program. Twenty eight-day mortality was not different between the 2 cohorts; however, identification of risk factors for death associated with blood factor use allows for restriction in high-risk populations, creates a discussion of futile care, and yields cost savings.
INTRODUCTION
Recombinant activated factor VII (rFVIIa; Novoseven) is a blood factor approved for use in hemophilia with inhibitors; Profilnine SD, a prothrombin complex concentrate (PCC) contains factors II, IX, and X and is approved for hemophilia B. Both agents are used off-label to reverse bleeding from vitamin K antagonism, trauma, or underlying coagulopathy. [1] [2] [3] These agents are favored because of their small administration volume; quick onset of action, 15 minutes; and prolonged effect in vivo, between 2.3 hours (rFVIIa) to 24 hours (Profilnine SD). 4, 5 The efficacy of blood factors in massive transfusion is equivocal. Bowles, et al reviewed all nonhemophiliac patients who received rFVIIa for massive hemorrhage at their institution from 2003 to 2005. 6 Eighteen patients met these criteria: 7 had underlying coagulopathy [leukemia (n 5 1), thrombotic thrombocytopenia purpura (n 5 1), and end-stage liver disease (n 5 5)]; all 7 died during the admission; 1 of myocardial infarction and the other 6 from multiorgan failure. The remaining 11 patients suffered from trauma or surgical procedures; 6 survived (54%). Eight of 18 patients received more than 1 dose of rFVIIa, including 4 of the 7 coagulopathic patients; 7 of the 8 died during admission. The authors concluded from this study that patients with underlying uncorrected coagulopathy and those who fail to respond to the initial dose of rFVIIa have a poorer prognosis and that treatment may be considered futile.
A second study by McMillen et al evaluated all patients with hemorrhagic shock receiving rFVIIa and massive transfusion support (10-12 units of packed red blood cells within 24 hours). 7 Seventy-two patients met these criteria; 45 died (62.5%). Patients were stratified based on survivorship. Patients who died were significantly older (median age 44 vs. 32 years), had longer prothrombin time (PT) (16.4 vs. 12.3), and higher international normalized ratio (INR) (1.6 vs. 1.2) at the initiation of the massive transfusion protocol. Age, baseline PT, and increased fresh frozen plasma administration statistically significantly increased the odds of death. This supports the hypothesis that underlying coagulopathy at presentation renders blood factor use futile.
Blood factors carry significant risks and contraindications, specifically arterial thrombosis and disseminated intravascular coagulopathy (DIC). A meta-analysis by Levi et al 1 evaluated the safety of rFVIIa in 35 clinical trials. Most patients received rFVIIa following spontaneous cerebral hemorrhage (31.3%), bleeding from hepatic-induced coagulopathy (27.8%), or trauma (18.7%). This analysis reported a 10% overall incidence of thromboembolic events in the rFVIIa group compared with 8.7% in patients who received placebo. The odds ratio (OR) for arterial thrombosis was greater than 1 in patients older than 65 years, those with spontaneous cerebral hemorrhage, and liver failure (2.43, 1.67, and 2.19, respectively). There are no reports of thrombosis in 3 studies evaluating the safety and efficacy of PCC use. 2, 3, 8 The absence of thrombosis in published literature should not be considered evidence of absence given similar mechanism of action to rFVIIa. Finally, these marginally efficacious agents are expensive: rFVIIa is $2.20/mg and PCC is $1.32/unit compared with $35/plasma unit.
Off-label blood factor use has marginal benefit, potential serious adverse effects, and high monetary cost. This led to the development and implementation of a pharmacist-led blood factor stewardship program at a tertiary care academic medical hospital. This study reports the mortality and morbidity results of a prospective stewardship program in high-risk patients with an additional goal of cost reduction.
METHODS
Beginning June 2013, all orders for off-label rFVIIa and PCC were prospectively reviewed by a single clinical pharmacist. Orders were discussed with the primary team regarding indication, patient-specific contraindications, appropriate dosing, and timing. Contraindications included the following: mechanical hardware, DIC or thromboembolism within 6 months. Vascular procedures considered to be high risk warranting blood factor support included tunneled line placement with INR $ 2.5, transjugular liver biopsy with INR $ 2, right heart catheterization with INR . 1.6, and transjugular intrahepatic portosystemic shunt; high-risk nonvascular procedures included renal biopsy, biliary interventions, and nephrostomy tube placement. Blood factor support was used in lower risk procedures when clinically indicated. Blood factors for massive transfusion were evaluated for the presence of contraindications and previous blood product use. If contraindications existed, the procedure was not considered high risk, or the use of blood factor was deemed to be futile, the order was voided.
The control group was a matched retrospective cohort from June 2012 through May 2013 of all nonhemophiliac patients who received blood factor at our institution. The primary endpoint of this study was 28-day mortality pre-and poststewardship. Secondary endpoints included change in INR from baseline following first dose of PCC or rFVIIa, adverse events, and units of concurrent blood product dispensed. Twenty eight-day mortality was evaluated from the last ordered dose in patients with multiple orders; multiple orders for the same patient were evaluated separately for secondary outcomes. Baseline demographic and clinical characteristics between the 2 groups were compared using the x 2 or Fisher exact test for categorical variables and the Student t test or Mann-Whitney U test as appropriate. Twenty eight-day mortality was analyzed with a logistic regression model that included active bleeding, whether drug use was for a heart catheterization, history of liver failure, whether drug was administered, factor stewardship implementation date (June 10, 2013). All statistical analyses were performed using SPSS 22 (SPSS, Inc., Chicago, IL). Statistical significance was set at 0.05. Indiana University institutional review board approval was granted for this study.
RESULTS
From June 2013 to May 2014, 42 patients had orders for blood factor; 14 did not receive drug because of contraindications. Mean age was 55.4 years (SD, 6 13.3). There were 72 patients in the control group from June 2012 to May 2013; mean age was 53.7 years (SD, 614.8). In both cohorts, there were multiple orders per patient: in the preimplementation group, there were 103 orders and in postimplementation, there were 34 orders for 28 patients. Table 1 describes the medical history. The mean baseline PT was 28 seconds in both groups.
Twenty eight-day mortality was equivalent preand poststewardship for all evaluated patients: pre, 52.9% (n 5 70) versus post, 50% (n 5 42), P 5 0.77 (Table 2) . Fifty percent of patients died within 28 days regardless of receipt of drug in the poststewardship group. Evaluation of underlying etiology and indication for blood factors by binary logistic regression model demonstrates a significant risk of death within 28 days in patients with underlying liver failure [OR, 2.9; 95% confidence interval (CI), 1.8-7.14] and those with active bleeding (OR, 2.91; 95% CI, 1.24-6.88). (Table 3) .
Use of plasma product significantly increased with stewardship implementation: median preintervention was 1 unit versus 4 units administered within 12 hours pre-and postinfusion of factor product (P 5 0.004), other blood products were not significantly changed (Table 4 ). Venous thromboembolism occurred 2.4% following stewardship implementation compared with none in the year before. Similarly, DIC occurred 9.5% postimplementation and never before. The absence of venous thromboembolism and DIC preimplementation may be attributed to a lack of monitoring or documentation. Mean change in INR prestewardship was 20.14 compared with 1.15 in the stewardship group; this is likely because of an increase in PCC use, which does not affect the INR as strongly as rFVIIa.
Total rFVIIa use declined with the stewardship; preimplementation, 48.6% (147 mg) of blood factor dispensed was rFVIIa, postimplementation, this decreased to 16.7% (30 mg) (P , 0.001). Total dollars dispensed for all blood factors preimplementation was $505,684, this decreased postimplementation to $130,145.30. Total savings over 1 year was $375,539.
DISCUSSION
Most patients in this study had an underlying diagnosis of liver failure. The use of blood factors in patients with liver failure is based on the hypothesis that an elevated PT/INR increases the likelihood of bleeding. However, the PT/INR does not accurately represent the hemostatic status in patients with liver failure because increases in von Willebrand and factor VIII and decreases in antithrombin and protein C, natural anticoagulants, are not accounted for. [9] [10] [11] This constellation of changes nullifies the accuracy of the PT/INR as a marker of bleeding and literature evaluating the bleeding risk during invasive procedures in patients with abnormal coagulation supports the hypothesis Although the implementation of the factor stewardship itself did not affect 28-day mortality, it is noted that factor administration did not improve mortality in a select subgroup of patients; most notably, those patients with active hemorrhage (OR, 2.91; 95% CI, 1.23-6.88) and those bleeding with a history of liver disease (OR, 2.9; 95% CI, 1.8-7.14). Retrospective studies in patients with active hemorrhage because of trauma or hemorrhagic shock have observed decreases in blood product administration with factor use, but survival has not been reported. 13, 14 Kwok et al evaluated rFVIIa in critically ill patients and found that although use as part of a massive transfusion order set inferred a high cost, it did not translate into an overall survival benefit. 15 It is reasonable to conclude that judicious use of factor product in critically ill or trauma patients with active hemorrhage is recommended, but ideal factor candidates have not been concluded from the literature.
The role of factor use in hepatic disease has generally evaluated surrogate endpoints such as PT goals and blood product administration with limited reports on survival. 16 Bendtsen et al 17 conducted a metaanalysis (n 5 497) of acute variceal bleeding in patients with end-stage liver disease receiving rFVIIa or placebo.
Although factor administration did decrease the recurrence of bleeding within 5 days of administration, it did not affect the 5-day or 40-day survival of patients. Similarly, our study did not demonstrate a long-term benefit of factor administration in patients with liver failure with active hemorrhage leading us to conclude that previously evaluated surrogate markers are inappropriate given the risk-benefit ratio of factor products.
This study included a small number of patients with a variety of indications. Additionally, multiple patients in both cohorts received more than 1 dose of blood factor, which makes it difficult to assess the underlying coagulopathy at the time of administration and the effect with regard to mortality. Other limitations include a lack of monitoring for DIC in the prestewardship group, which contributed to a significant finding of DIC at baseline in the postimplementation group and the retrospective nature of the study may have contributed to a decreased identification of thromboembolism following blood factor use.
Although the role of stewardship has been widely published and recommended for developing and instituting antimicrobials, there are limited data and recommendations in other areas of medication use. 18 As inferred by common practice, the utilization of order sets may help to curb or limit prescribing habits, but this may not be applicable in real time urgent or critical situations. In this regard, the authors would like to convey the importance of a stewardship program that allows real-time discussion with clinicians rather than medication reviews as a systematic process. In these acute situations, where costly medications with a narrow risk-benefit profile have the potential for treating complications, it is necessary for real-time patient assessment and health care provider dialog.
CONCLUSION
Although no difference was observed in 28-day mortality among patients receiving rFVIIa pre-or postimplementation of a pharmacy stewardship, this study highlights that in routine clinical practice the futility and potential misuse of high-risk expensive drugs can be controlled. Patient characteristics and rationale for use may vary from institution to institution and the implementation of stewardship should be considered if excess or misuse of rFVIIa is observed. Implementation with a dedicated trained hematology pharmacist is reasonable, similar to the process of having a trained dedicated pharmacist for antimicrobial stewardship.
